Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

VTX958 Versus Placebo para o Tratamento da Psoríase Moderada a Grave (Serenity PsO)

29 de outubro de 2026 atualizado por: Ventyx Biosciences, Inc

Um estudo de fase 2, multicêntrico, randomizado, duplo-cego, controlado por placebo, de grupo paralelo para avaliar a eficácia e a segurança do VTX958 em participantes com psoríase moderada a grave

This is a study to understand if taking VTX958 is safe and effective in participants diagnosed with moderate to severe psoriasis (PsO). Approximately 200 patients will take VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, or placebo.

The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 16-week double-blind period (a participant receives active Dose A, Dose B, Dose C, Dose D, or placebo), a 16-week Long Term Extension (LTE) period, a 36-week Open Label Extension (OLE) period and a 4-week Follow-Up Period. The maximal duration of treatment will be approximately 16 months.

Visão geral do estudo

Status

Rescindido

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

222

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Fredericton, Canadá
        • Local Site # 124012
      • Mississauga, Canadá
        • Local Site # 124010
      • Montreal, Canadá
        • Local Site # 124002
      • North Bay, Canadá
        • Local Site # 124004
      • Oshawa, Canadá
        • Local Site # 124011
      • Peterborough, Canadá
        • Local Site # 124007
      • Québec, Canadá
        • Local Site # 124008
      • Toronto, Canadá
        • Local Site # 124005
      • Windsor, Canadá
        • Local Site # 124006
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35205
        • Local Site # 840012
      • Birmingham, Alabama, Estados Unidos, 35244
        • Local Site # 840006
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85032
        • Local Site # 840028
    • Arkansas
      • Bryant, Arkansas, Estados Unidos, 72022
        • Local Site # 840032
      • North Little Rock, Arkansas, Estados Unidos, 72117
        • Local Site # 840041
    • California
      • Fountain Valley, California, Estados Unidos, 92708
        • Local Site # 840031
      • Lomita, California, Estados Unidos, 90717
        • Local Site # 840026
      • Santa Rosa, California, Estados Unidos, 95405
        • Local Site # 840019
      • Sherman Oaks, California, Estados Unidos, 91403
        • Local Site # 840003
    • Florida
      • Boca Raton, Florida, Estados Unidos, 33486
        • Local Site # 840040
      • Doral, Florida, Estados Unidos, 33122
        • Local Site # 840011
      • Hialeah, Florida, Estados Unidos, 33012
        • Local Site # 840023
      • Miami Lakes, Florida, Estados Unidos, 33104
        • Local Site # 840021
      • North Miami Beach, Florida, Estados Unidos, 33162
        • Local Site # 840044
      • Ocala, Florida, Estados Unidos, 34470
        • Local Site # 840010
      • Tampa, Florida, Estados Unidos, 33607
        • Local Site # 840004
      • Tampa, Florida, Estados Unidos, 33613
        • Local Site # 840001
      • West Palm Beach, Florida, Estados Unidos, 33406
        • Local Site # 840045
    • Georgia
      • Marietta, Georgia, Estados Unidos, 30060
        • Local Site # 840029
    • Indiana
      • Clarksville, Indiana, Estados Unidos, 47129
        • Local Site # 840035
      • Indianapolis, Indiana, Estados Unidos, 46250
        • Local Site # 840005
      • Plainfield, Indiana, Estados Unidos, 46168
        • Local Site # 840030
    • Kentucky
      • Louisville, Kentucky, Estados Unidos, 40241
        • Local Site # 840013
    • Maryland
      • Rockville, Maryland, Estados Unidos, 20850
        • Local Site # 840022
    • Massachusetts
      • Brighton, Massachusetts, Estados Unidos, 02135
        • Local Site # 840008
    • Michigan
      • Bay City, Michigan, Estados Unidos, 48706
        • Local Site # 840016
      • Fort Gratiot, Michigan, Estados Unidos, 48059
        • Local Site # 840007
      • Troy, Michigan, Estados Unidos, 48084
        • Local Site # 840002
    • Minnesota
      • New Brighton, Minnesota, Estados Unidos, 55112
        • Local Site # 840034
    • Missouri
      • Saint Joseph, Missouri, Estados Unidos, 64506
        • Local Site # 840024
    • New Hampshire
      • Portsmouth, New Hampshire, Estados Unidos, 03801
        • Local Site # 840027
    • North Carolina
      • Wilmington, North Carolina, Estados Unidos, 28405
        • Local Site # 840042
    • Ohio
      • Mason, Ohio, Estados Unidos, 45040
        • Local Site # 840037
    • Oregon
      • Portland, Oregon, Estados Unidos, 97223
        • Local Site # 840009
    • South Dakota
      • Rapid City, South Dakota, Estados Unidos, 57702
        • Local Site # 840038
    • Tennessee
      • Murfreesboro, Tennessee, Estados Unidos, 37130
        • Local Site # 840015
    • Texas
      • Pflugerville, Texas, Estados Unidos, 78660
        • Local Site # 840039
    • Washington
      • Spokane, Washington, Estados Unidos, 99202
        • Local Site # 840014
      • Bialystok, Polônia
        • Local Site # 616015
      • Bialystok, Polônia
        • Local Site # 616016
      • Katowice, Polônia
        • Local Site # 616001
      • Krakow, Polônia
        • Local Site # 616014
      • Lodz, Polônia
        • Local Site # 616004
      • Lublin, Polônia
        • Local Site #616010
      • Mikołów, Polônia
        • Local Site # 616011
      • Nowa Sól, Polônia
        • Local Site # 616009
      • Ostrowiec Świętokrzyski, Polônia
        • Local Site # 616003
      • Poznan, Polônia
        • Local Site # 616008
      • Szczecin, Polônia
        • Local Site # 616007
      • Szczecin, Polônia
        • Local Site # 616013
      • Warsaw, Polônia
        • Local Site # 616005
      • Wroclaw, Polônia
        • Local Site # 616002
      • Wroclaw, Polônia
        • Local Site # 616006
      • Wroclaw, Polônia
        • Local Site # 616018

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Male or female participant aged 18 years or older.
  • History of primarily plaque psoriasis for at least 6 months prior to the screening visit.
  • Has had stable psoriasis conditions for at least 3 months before screening.
  • Has moderate to severe plaque psoriasis as defined by a PASI score of ≥ 12 and an sPGA score of ≥ 3 at screening and Day 1.
  • Has plaque psoriasis covering ≥ 10% of the total BSA at screening and Day 1.
  • Deemed by the investigator to be eligible for phototherapy or systemic therapy.
  • Females of childbearing potential must agree to use a highly effective contraceptive method from at least 4 weeks prior to Day 1 until at least 4 weeks after the last dose of study product.

Exclusion Criteria:

  • Female who is breastfeeding, pregnant, lactating, or who is planning to become pregnant during the study.
  • Has evidence of erythrodermic, pustular, predominantly inverse or guttate psoriasis, or drug-induced psoriasis.
  • History of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
  • Participant is known to have immune deficiency or is immunocompromised.
  • Has immune-mediated conditions commonly associated with psoriasis, such as psoriatic arthritis, active uveitis, inflammatory bowel disease, that currently require systemic treatment (including corticosteroids, immunosuppressants, or biologics).

Note: Participants with immune-mediated conditions commonly associated with psoriasis that do not require systemic treatment may be included in the study.

  • Has used any topical medication that could affect psoriasis (including corticosteroids, retinoids, vitamin D analogues [such as calcipotriol], Janus kinase [JAK] inhibitors, or tar) within 2 weeks prior to Day 1.
  • Has used any systemic treatment that could affect psoriasis (including corticosteroids, oral retinoids, immunosuppressive medication, anakinra, methotrexate, cyclosporine, oral JAK inhibitors, or apremilast) within 4 weeks prior to Day 1.

Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed.

  • Participant has received any ultraviolet B (UVB) phototherapy (including tanning beds) or excimer laser within 4 weeks prior to Day 1.
  • Participant has had psoralen and ultraviolet A (PUVA) treatment within 4 weeks prior to Day 1.
  • Participant has received treatment with an investigational or marketed TYK2 inhibitor.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: VTX958 300 mg BID (Placebo Controlled)

Participants received one 300 milligram (mg) VTX958 tablet administered orally twice daily (BID) to maintain the blind in Period 1.

VTX958 administered orally

Experimental: VTX958 225 mg BID (PC)

Participants received one 225 mg VTX958 tablet administered orally BID to maintain the blind in Period 1.

VTX958 administered orally

Experimental: VTX958 300 mg QD (PC)

Participants received 300 mg VTX958 tablet administered orally once daily (QD), and matching placebo tablets administered orally QD to maintain the blind in Period 1.

VTX958 administered orally

Experimental: VTX958 50 mg BID (PC)

Participants received 50 mg VTX958 tablet administered orally BID and matching placebo tablets administered orally BID to maintain the blind in Period 1.

VTX958 administered orally

Comparador de Placebo: Placebo BID (PC)

Participants received placebo tablets matched to VTX958, administered BID to maintain the blind in Period 1.

Placebo administered orally

Experimental: Long Term Extension Period (LTE): VTX958 300 mg BID

Participants who received 300 mg VTX958 dose administered orally BID in Period 2.

VTX958 administered orally

Experimental: LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID

Participants who received 225 mg VTX958 at Period 1 continued to receive 225 mg VTX958 dose administered orally BID in Period 2.

VTX958 administered orally

Experimental: LTE: VTX958 300 mg QD (PC)/ VTX958 300 mg QD

Participants who received 300 mg VTX958 at Period 1 continued to receive 300 mg VTX958 dose administered orally QD in Period 2.

VTX958 administered orally

Experimental: LTE: VTX958 50 mg BID (PC)/ VTX958 50 mg BID

Participants who received 50 mg VTX958 at Period 1 continued to receive 50 mg VTX958 dose administered orally BID in Period 2.

VTX958 administered orally

Experimental: Open Label Extension (OLE): VTX958 300 mg BID

Participants who received 300 mg VTX958 dose administered orally BID in Period 3.

VTX958 administered orally

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Period 1: Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 16
Prazo: Week 16

Participants achieving a ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI) score (PASI 75) at Week 16 were considered responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

As pre-specified in the statistical analysis plan this analysis was planned to compare each VTX958 dose with Placebo.

Week 16
Period 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Observed During the Study of VTX958
Prazo: Baseline up to week 16

The number of participants with TEAEs and SAEs observed during the study of VTX958.

A TEAE is any condition that was not present prior to treatment with the study product but appeared following treatment, was present at treatment initiation but worsened during treatment, or was present at treatment initiation but resolved and then reappeared while the individual was on treatment (regardless of the intensity of the AE when the treatment was initiated).

An SAE or reaction is any untoward medical occurrence that, at any dose has any of the following consequences:

  • Results in death
  • Is life-threatening
  • Requires in-patient hospitalization or prolongation of existing hospitalization
  • Results in persistent or significant disability/incapacity
  • Is a congenital anomaly/birth defect
Baseline up to week 16

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Period 1: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 16
Prazo: Week 16

Percentage of participants achieving a sPGA score of 0 (clear) or 1 (almost clear) with ≥2-grade improvement from baseline at Week 16. The investigator assessed psoriasis severity on a 5-point scale from 0 (clear) to 4 (severe):

0 = Clear: No signs of psoriasis; post-inflammatory hyperpigmentation may occur

  1. = Almost clear: Normal to pink lesions; no thickening; no or minimal focal scaling
  2. = Mild: Pink to light red color; slight thickening; mainly fine scaling
  3. = Moderate: Dull bright red erythema; moderate thickening; moderate scaling
  4. = Severe: Bright to deep red; severe thickening with hard edges; coarse scaling covering most or all lesions
Week 16
Period 1: Change From Baseline in PASI Score at Week 16
Prazo: Baseline, Week 16

Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects.

The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Baseline, Week 16
Period 1: Percent Change From Baseline in PASI Score at Week 16
Prazo: Baseline, Week 16

Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects.

The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Baseline, Week 16
Percentage of Participants Achieving ≥90% Reduction From Baseline in PASI-90 at Week 16
Prazo: Week 16

Percentage of participants achieving ≥90% reduction from baseline in PASI-90 at Week 16. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Week 16
Period 1: Percentage of Participants Achieving ≥100% Reduction From Baseline in PASI-100 at Week 16
Prazo: Week 16

Percentage of participants achieving ≥100% reduction from baseline in PASI-100 at Week 16. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Week 16
Period 1: Change From Baseline in Dermatology Life Quality Index (DLQI) at 16 Weeks
Prazo: Baseline, Week 16

The DLQI is a simple 10-question validated questionnaire where, except for question 7, each question is rated from 0 (Not at all) to 3 (Very much). If question 7 is answered 'yes', this question is assigned a score of 3. If question 7 is answered 'No' or 'Not Relevant', this question is assigned a score 0, except if either 'a lot' or 'a little' is ticked. If so, this question is assigned a score of 2 or 1, respectively. Then, the DLQI total score is the sum of the 10 questions and ranges from 0 to 30, where higher scores indicate worst disease severity.

Baseline, Week 16
Period 1: Change From Baseline in the Percentage of Body Surface Area (BSA) Affected at Week 16
Prazo: Baseline, Week 16

Least square mean was determined with MMRM using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, prior biologic treatment for psoriasis (Yes/No), and baseline score as a covariate, with participant as a random effect baseline is the last non-missing pre-dose value.

BSA is a measurement of the affected skin area. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). The overall BSA affected by psoriasis plaques is estimated based on the palm area of the participant hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total BSA. Negative change from baseline indicates improvement.

Baseline, Week 16

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Snehal Naik, PhD, Ventyx Biosciences, Inc

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

17 de novembro de 2022

Conclusão Primária (Real)

25 de setembro de 2023

Conclusão do estudo (Real)

20 de dezembro de 2023

Datas de inscrição no estudo

Enviado pela primeira vez

2 de dezembro de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

8 de dezembro de 2022

Primeira postagem (Real)

19 de dezembro de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

29 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • VTX958-201
  • 2022-002887-59 (Número EudraCT)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .